Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE

Knee OA, to inject or not to inject: the great debate 📣 A thread👇🏼👇🏼👇🏼 Maglette Klotenburg argues in favor, with moderation IA GC improves pain Repetitive injections can be harmful @RheumNow #ACR23 https://t.co/3p4UVLngpx

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz

In case you missed it! AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #colchicine, #placebo 3/4 flared vs <1/2 w drug. My critique is why not optimize allopurinol dose - only 300 mg, no fuboxastat L15 #ACR23 @RheumNow @ACRheum https://t.co/NZWLpWXT51

Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0

Q for Rheumatologists: How often do you counsel appropriate SLE patients about cervical ca screening and/or vaccination? Re: PAPILUP Study A#1479 #ACR23 - shows PAP findings of HR-HPV+abnml cytology comparable to HIV+ pts @RheumNow

L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6

What happens when you stop #steroids and/ immunosuppressive Rx in Pts in remission for at least 1 yr in #IgG4 disease? You are likely guessing correctly Pts flare! Don’t stop Rx ?taper 🤷‍♀️ Like RA Rx - if stop Rx = flares Large RCT from China L16 #ACR23 @RheumNow @RheumNow

Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest ⁦@RheumNow⁩ ⁦@ACRheum⁩ L15 In larger RCT now! https://t.co/zssjgpydVY

#IA Injection in #knee #OA. TLC599 vs #dexamethasone vs saline #RCT-blinded. Both active #Rx better than #PBO. Some differences in average daily pain between active drugs. Not sure where it may fit in? After IA steroid failure? L18 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/rLh6ISBpUw

Inflammation in interstitial fibrosis & tubular atrophy (i-IFTA) is assoc w/ GFR loss accdg to this study by Dr SMalvica et al. ✳️In pts w/ mod-to-severe IFTA, the degree of i-IFTA was assoc'd with higher risk of GFR loss #ACR23 ABST2552 @RheumNow https://t.co/7iA0nzbmgM

Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Significantly lower risk ETN (HR 0.70), UST (HR 0.56) vs ADA. Others similar. Abstr#2566 #ACR23 @RheumNow https://t.co/GGDvRxP9ht https://t.co/Ol7G1OG73t

Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF Different mechanisms of damage and progression based on ab profile? @RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ

#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ

Beware of the « HOT stuff 🌶️ bias » In his very didactic catalogue of bias, Timothy McAlindon particularly warns us against the hot stuff, or the tendency to be less rigorous in the scientific approach when a topic is fashionable @RheumNow #ACR23 https://t.co/rS8lItDrGS